

Data supplement to Wu et al. Complications and mortality in patients with schizophrenia and diabetes: population-based cohort study. Br J Psychiatry  
doi: 10.1192/bjp.bp.113.143925

**Table DS1** Hazard Ratios for Macrovascular and Microvascular Complications, and Mortality of Schizophrenia Patients and Comparison Subjects, Total and Stratified by Patient Characteristics (*n* = 22,494)

	Complications				Mortality	
	Macrovascular		Microvascular		All cause	
<b>Model 1</b>	1.28	(1.17 , 1.40)	1.16	(1.05 , 1.28)	3.54	(3.16 , 3.96)
<b>Model 2</b>	1.53	(1.37 , 1.72)	1.08	(0.94 , 1.24)	4.05	(3.55 , 4.62)
<b>Model 3</b>	1.51	(1.34 , 1.70)	1.05	(0.91 , 1.20)	3.86	(3.38 , 4.42)
<b>Model 4</b>	1.49	(1.32 , 1.68)	1.05	(0.91 , 1.21)	3.68	(3.21 , 4.22)

Model 1: Unadjusted  
 Model 2: Adjusted with health system utilization  
 Model 3: Adjusted with health system utilization, psychiatric comorbidity and use of psychotropic agent  
 Model 4: Adjusted with all covariates

**Table DS2.** Hazard ratios for macrovascular, microvascular complications, and mortality of schizophrenia and covariates

	Macrovascular complication		Microvascular complication		All-cause mortality	
	HR	95% CI	HR	95% CI	HR	95% CI
Schizophrenia	1.49	(1.32 , 1.68)	1.05	(0.91 , 1.21)	3.68	(3.21 , 4.22)
Comorbidity						
Hypertension	1.66	(1.47 , 1.86)	1.08	(0.94 , 1.25)	1.27	(1.12 , 1.44)
Dyslipidemia	1.03	(0.91 , 1.16)	0.92	(0.80 , 1.07)	0.72	(0.62 , 0.82)
Chronic liver diseases	1.06	(0.93 , 1.21)	1.00	(0.85 , 1.17)	1.26	(1.11 , 1.44)
Chronic pulmonary diseases	1.30	(1.17 , 1.46)	1.01	(0.88 , 1.16)	1.25	(1.11 , 1.40)
Malignancy	1.05	(0.79 , 1.40)	0.95	(0.66 , 1.35)	3.56	(3.01 , 4.21)
Depressive disorders	0.87	(0.76 , 1.01)	1.06	(0.90 , 1.25)	0.87	(0.76 , 0.99)
Anxiety disorders	0.87	(0.77 , 0.98)	0.83	(0.72 , 0.97)	0.91	(0.81 , 1.03)
Alcohol and substance use	1.34	(1.14 , 1.58)	1.71	(1.43 , 2.04)	1.89	(1.65 , 2.17)
Medication use						
ACEI/ARB	1.09	(0.94 , 1.25)	0.98	(0.81 , 1.18)	0.94	(0.78 , 1.12)
Beta blocker	0.97	(0.87 , 1.08)	0.81	(0.71 , 0.93)	0.86	(0.77 , 0.97)
Calcium channel blocker	1.40	(1.23 , 1.60)	1.35	(1.14 , 1.60)	1.08	(0.93 , 1.26)
Diuretics	1.30	(1.14 , 1.48)	1.58	(1.35 , 1.85)	1.57	(1.37 , 1.81)
Lipid lowering agent	1.05	(0.89 , 1.24)	0.88	(0.71 , 1.10)	0.85	(0.69 , 1.04)
NSAID	0.89	(0.80 , 1.00)	0.90	(0.80 , 1.02)	0.81	(0.72 , 0.91)
Antidepressants	1.21	(1.07 , 1.38)	1.10	(0.94 , 1.29)	1.14	(1.01 , 1.29)
Healthy system utilization						
Number of non-psychiatric outpatient visits						
<10	1.00	reference	1.00	reference	1.00	reference
10-19	0.89	(0.79 , 1.01)	0.77	(0.67 , 0.89)	0.94	(0.82 , 1.08)
≥20	0.98	(0.86 , 1.12)	0.92	(0.80 , 1.07)	1.14	(0.99 , 1.31)
Number of psychiatric outpatient visits						
<10	1.00	reference	1.00	reference	1.00	reference
10-19	0.74	(0.65 , 0.85)	0.96	(0.82 , 1.13)	0.76	(0.67 , 0.86)
≥20	0.80	(0.67 , 0.95)	1.25	(1.03 , 1.53)	0.85	(0.72 , 1.00)
Hospitalization						
Non-psychiatric	1.51	(1.34 , 1.71)	1.66	(1.45 , 1.91)	1.78	(1.58 , 2.01)
Psychiatric	0.82	(0.72 , 0.94)	1.04	(0.89 , 1.21)	0.96	(0.85 , 1.08)